In a review of 200 patients with a wide spectrum of cancer diagnoses, researchers found that after full vaccination, 94 percent of patients overall demonstrated seroconversion, which was determined by the presence of antibodies to the SARS-CoV-2 spike protein. Response rates were very high among patients with solid tumors and were lower in people with certain blood cancers, but even the majority of those patients mounted an immune response.